<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="82208">
  <stage>Registered</stage>
  <submitdate>10/08/2007</submitdate>
  <approvaldate>12/12/2007</approvaldate>
  <actrnumber>ACTRN12607000633482</actrnumber>
  <trial_identification>
    <studytitle>Global Prevention of Asthma in Children Study</studytitle>
    <scientifictitle>A Phase II Multicenter, Controlled, Double-Blind Study Using Immunoprophylaxis in the Primary Prevention of Allergic Disease</scientifictitle>
    <utrn />
    <trialacronym>GPAC</trialacronym>
    <secondaryid>ClinicalTrials.gov - NCT00346398</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Allergic Rhinitis</healthcondition>
    <healthcondition>Asthma</healthcondition>
    <conditioncode>
      <conditioncode1>Respiratory</conditioncode1>
      <conditioncode2>Asthma</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>House Dust Mites - 7.5 mcg/0.2ml (Dermatophagoides pteronyssinus &amp; Dermatophagoides farinae); Cat (11.3 mcg/0.2ml) and Timothy Grass (15.0 mcg/0.2ml) or matching placebo orally once daily for 12 months</interventions>
    <comparator>Sham allergen - 0.6ml orally once daily for 12 months</comparator>
    <control>Placebo</control>
    <interventioncode>Prevention</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>To assess whether oral immunoprophylaxis reduces allergic sensitization to any of the treatment mix allergens 3 years after the end of treatment. This will be measured via a skin prick test.</outcome>
      <timepoint>4 years</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>To assess whether oral immunoprophylaxis reduces the incidence of asthma 3 years after completing treatment. This will be assessed by incidences of wheeze and/or doctor diagnosis</outcome>
      <timepoint>4 years</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1. Diagnosed with eczema (atopic dermatitis) 
2. Family history of eczema, allergic rhinitis, or asthma 
3. Allergy to one or more of the following: egg white, cows milk, peanut, or soybean 
4. Weigh at least 8.0 kg 
5. Parent or guardian willing to provide informed consent</inclusivecriteria>
    <inclusiveminage>12</inclusiveminage>
    <inclusiveminagetype>Months</inclusiveminagetype>
    <inclusivemaxage>30</inclusivemaxage>
    <inclusivemaxagetype>Months</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1. Allergy to house dust mite, cat, or timothy grass 
2. Born prematurely (before 36th week's gestation) 3. Previous diagnosis of asthma OR have had 3 or more distinct episodes of wheeze during the first year of life 
3. Chronic pulmonary disease 
4. Chronic disease requiring therapy 
5. Past or current treatment with systemic immunomodulator medication
6. Past or current treatment with allergen-specific immunotherapy
7. Received 10 or more days of systemic steroids in the 3 months prior to study entry 
8. Orofacial abnormalities that are likely to interfere with the volunteer's ability to take study treatment 
9. Participated in another clinical study within the 3 months prior to study entry</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>central randomization by computer</concealment>
    <sequence>Participants will be randomized in blocks to the treatment group or the placebo group using a one-to-one ratio. Randomization will be stratified by investigational site to ensure an approximately equal allocation to each group within each site.</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures>Double blind placebo controlled randomised clinical trial</designfeatures>
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate>1/06/2006</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>200</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <postcode>6008</postcode>
    <postcode>3052</postcode>
    <countryoutsideaustralia>
      <country>United States of America</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Berlin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Sweden</country>
      <state>Stockholm</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Government body</primarysponsortype>
    <primarysponsorname>National Institute of Allergy and Infectious Diseases</primarysponsorname>
    <primarysponsoraddress>Room 3093
6610 Rockledge Drive
Bethesda MD 20892-7640</primarysponsoraddress>
    <primarysponsorcountry>United States of America</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>Immune Tolerance Network</fundingname>
      <fundingaddress>Suite 3515
185 Berry St
San Francisco CA 94107</fundingaddress>
      <fundingcountry>United States of America</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>None</sponsorname>
      <sponsoraddress>None</sponsoraddress>
      <sponsorcountry>United States of America</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary />
    <trialwebsite>wwww.globalasthmastudy.com</trialwebsite>
    <publication>None</publication>
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Princess Margaret Hospital for Children Ethics Committee</ethicname>
      <ethicaddress>Roberts Road
Subiaco WA 6008</ethicaddress>
      <ethicapprovaldate>18/09/2003</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Peter Sly</name>
      <address>100 Roberts Road
Subiaco WA 6008</address>
      <phone>+61 8 94897810</phone>
      <fax>+61 9 94897700</fax>
      <email>peters@ichr.uwa.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Peter Sly</name>
      <address>100 Roberts Road
Subiaco WA 6008</address>
      <phone>+61 8 94897777</phone>
      <fax>+61 9 94897700</fax>
      <email>peters@ichr.uwa.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Carlie Dunford</name>
      <address>100 Roberts Road
Subiaco WA 6008</address>
      <phone>+61 8 94897813</phone>
      <fax>+61 9 94897700</fax>
      <email>carlied@ichr.uwa.edu.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>